Skip to main content
. Author manuscript; available in PMC: 2009 Apr 1.
Published in final edited form as: Semin Hematol. 2008 Apr;45(2):95–103. doi: 10.1053/j.seminhematol.2008.02.001

Table 2.

Combination regimens with concurrent Rituximab in CLL/SLL

Reference (Authors / year) Prior therapy Rituximab dose (mg/m2) Cycles Other agents Evaluable patients ORR (CR)
Byrd et al., 2001 Yes 375 q4wks 6 Flu 51 90% (47%)
Schulz et al., 2002 Yes 375 q4wks 4 Flu 31 87% (32%)
Wierda et al., 2005 Yes 500 q4wks 6 Flu/Cy 177 73% (25%)
Keating et al, 2005 No 500 q4wks 6 Flu/Cy 300 94% (72%)
Wierda et al, 2006 Yes 500 q4wks 6 Flu/Cy/A 78 65% (24%)
Kay et al, 2007 No 375 q3wks 6 Pent/Cy 64 91% (41%)

Abbreviations: Fludarabine (Flu), Cyclophosphamide (Cy), Alemtuzumab (A), Pentostatin (Pent)